For instance, in the mouse B16 melanoma model, phosphofructokinase 2/ fructose-2, 6-bisphosphatase 3 (PFKFB3) stimulates glycolytic activity and lactic acid generation in tumor cells, while PFK-158, its inhibitor, enhances the therapeutic response of antibodies against CTLA-4 [58,59]. This evidence concerns the gene CTLA4 and neoplasm.